Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Expected to Announce Quarterly Sales of $55.97 Million

Equities analysts expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to announce sales of $55.97 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Osmotica Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $49.13 million and the highest estimate coming in at $62.80 million. Osmotica Pharmaceuticals reported sales of $66.35 million in the same quarter last year, which indicates a negative year-over-year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Osmotica Pharmaceuticals will report full-year sales of $231.97 million for the current year, with estimates ranging from $215.84 million to $248.10 million. For the next year, analysts expect that the business will report sales of $220.47 million, with estimates ranging from $189.93 million to $251.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.06. The firm had revenue of $57.53 million for the quarter, compared to analyst estimates of $57.90 million. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%.

OSMT has been the subject of a number of recent research reports. ValuEngine raised shares of Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Co reaffirmed a “buy” rating on shares of Osmotica Pharmaceuticals in a research note on Friday, August 9th. Jefferies Financial Group set a $10.00 target price on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 12th. Barclays initiated coverage on Osmotica Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “overweight” rating and a $11.00 price objective on the stock. Finally, Zacks Investment Research lowered Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $13.00.

Several hedge funds have recently modified their holdings of the company. Sofinnova Investments Inc. grew its holdings in Osmotica Pharmaceuticals by 107.5% during the second quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock worth $1,996,000 after acquiring an additional 272,109 shares during the period. Geode Capital Management LLC acquired a new stake in Osmotica Pharmaceuticals during the 4th quarter worth about $668,000. Acadian Asset Management LLC lifted its stake in Osmotica Pharmaceuticals by 277.5% during the second quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock valued at $206,000 after buying an additional 39,584 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Osmotica Pharmaceuticals in the second quarter worth about $142,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Osmotica Pharmaceuticals in the second quarter worth approximately $120,000. Institutional investors own 7.01% of the company’s stock.

Shares of NASDAQ:OSMT traded up $0.21 on Friday, reaching $3.21. 13,160 shares of the company were exchanged, compared to its average volume of 81,863. Osmotica Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $9.90. The company has a current ratio of 1.78, a quick ratio of 1.49 and a debt-to-equity ratio of 1.05. The firm has a market cap of $154.56 million and a price-to-earnings ratio of -6.27. The company has a 50-day moving average of $3.10 and a 200-day moving average of $3.92.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: Moving Average (MA)

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.